Screener / SEC EDGAR /CIK 0001649094 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Vaxcyte, Inc. PCVX

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of PCVX's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Apr 10, 2025
Questions asked 18 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 4 UPLOAD
  2. 2. Questions in them 18 numbered comments
  3. 3. Company replies 4 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 34 days or less from the first letter to the closing letter.

Form 10-K for the fiscal year ended December 31, 2024

2025-04-10 to 2025-05-14 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2025-05-14
SEC asked
You disclose on page 106 that do not allocate all of your costs by vaccine candidates, as your research and development expenses include internal costs, such as payroll and other personnel expenses, which are not tracked by vaccine candidate.
Rest of the question

Please provide revised disclosure to be included in future filings to address the following: • Clarify which expenses you do allocate by project and clarify if you track any expenses by candidate. To the extent you do track any research and development expenses by program, provide a breakdown of the expenses tracked by project. If you do not track external expenses by program, break out external research and development costs by clinical and preclinical. If you cannot disaggregate these • 1. amounts, please disclose that fact and explain why not. • For all other research and development expenses. provide us with other quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e. by nature or type of expense) which should reconcile to total research and development expense on the Statements of Operations. We note that you included a break out of research and development expenses by type in the 10-K for the year ended December 31, 2023.

PCVX answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that we track our research and development (“R&D”) expenses by major types of expense, and we do not have a systematic approach to allocate R&D expenses by candidate, program and/or project. Our R&D expenses include:

1)External costs:

a)Product manufacturing costs: This includes costs related to acquiring, developing, and manufacturing supplies for clinical trials and to prepare for potential future commercial launches, including fees paid to contract manufacturing organizations.

b)Clinical costs: This includes
Rest of the answer

costs and expenses related to agreements with contract research organizations, investigator sites, and consultants to conduct clinical trials.

c)R&D consumables costs, laboratory supplies and equipment costs.

d)Facility and allocated costs.

e)Other expenses, which primarily include professional and consulting services costs.

Read in the reply

Also in this review: closing letter, 2025-05-14

Form S-1

2019-11-07 to 2020-06-09 · 17 questions · 3 letters from the SEC, 3 from the company
No closing letter
Risk factors
SEC letter of Nov 7, 2019 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary, page 1
SEC asked (1)
Please revise your statement here and elsewhere in the prospectus that SVX-24 has the potential to become the "standard of care." This statement implies an expectation of regulatory approval and is inappropriate given the length of time and uncertainty with respect to securing marketing approval.
PCVX answered

No reply letter found.

Our Pipeline, page 3
SEC asked (2)
Please remove your statement that you believe that your preclinical study results may be predictive of clinical trial results based on your use of the same rabbit model used to develop each of the PCVs approved to date. It is not appropriate to imply that success in animal models may result in success in humans.
PCVX answered

No reply letter found.

Our Pipeline, page 3
SEC asked (3)
Please expand to state whether you have received any feedback from the FDA as to whether they would accept your intended approach of seeking regulatory approval based on a demonstration of non-inferiority to the standard of care rather than on clinical field efficacy studies.
PCVX answered

No reply letter found.

Our Strategy, page 4
SEC asked (4)
We note your disclosure that your strategy is to "rapidly advance" SVX-24 through INDenabling activities, clinical development and regulatory approval. Please revise this statement and any similar disclosure to remove any implication that you will be successful in commercializing your product candidates in a rapid or accelerated manner as such statements are speculative.
PCVX answered

No reply letter found.

Risk Factors Summary, page 5
SEC asked (5)
We note several statements in the prospectus, including in a risk factor, regarding pursuing a streamlined approach to regulatory approval of your vaccines based on how other vaccines have obtained regulatory approval.
Rest of the question

Please add a risk factor to this section to make it clear that there can be no assurance that your intended approach will be sufficient for regulatory approval or that regulators will not require field efficacy trials or longer trials with more participants than you currently anticipate.

PCVX answered

No reply letter found.

Implications of Being an Emerging Growth Company, page 7
SEC asked (6)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
PCVX answered

No reply letter found.

Use of Proceeds, page 66
SEC asked (7)
We note your disclosure that you intend to use a portion of the proceeds to fund the clinical and ongoing development of your vaccine candidates. Please specifically disclose how far you expect the proceeds from the offering to allow you to proceed in the development of each of these candidates.
PCVX answered

No reply letter found.

Business · Drawbacks for Current PCVs, page 102
SEC asked (8)
Please make the disclosure under the charts in Figure 4 and Figure 5 on page 103 more legible.
PCVX answered

No reply letter found.

Intellectual Property, page 118
SEC asked (9)
Please specify to which of your product candidates your pending and current patents relate.
PCVX answered

No reply letter found.

Amended and Restated Agreement with Sutro Biopharma, page 119
SEC asked (10)
We note your disclosure that royalties are payable until the later of the expiration of the last valid claim in the licensed patents or 10 years after the first commercial sale. Please specify when the licensed patents are expected to expire.
PCVX answered

No reply letter found.

University of California, San Diego License Agreement, page 120
SEC asked (11)
We note your disclosure that royalties are payable until expiration of the last licensed patent. Please specify when the current last licensed patent is expected to expire. Principal Stockholders, page 156
PCVX answered

No reply letter found.

University of California, San Diego License Agreement, page 120
SEC asked (12)
We note your disclosure regarding certain individuals who share or may be deemed to share investment and dispositive power over the shares held by certain entities. It is not clear whether those are the sole individuals who have voting and investment control.
Rest of the question

In that regard, please revise your disclosure to identify all of the natural person or persons who have voting and investment control of the shares held by Abingworth Bioventures VI, LP, Longitude Venture Partners II, L.P., and TPG Growth IV Switcheroo, L.P.

PCVX answered

No reply letter found.

Description of Capital Stock, page 158
SEC asked (13)
We note that you refer shareholders to, in part, the relevant provisions of the Delaware General Corporation Law. It is not appropriate to qualify your disclosure by reference to information that is not included in the filing or filed as an exhibit. Please revise accordingly.
PCVX answered

No reply letter found.

General
SEC asked (14)
Please provide us proofs of all graphics, visual, or photographic information you will provide in the printed prospectus prior to its use, for example in a preliminary prospectus. Please note that we may have comments regarding this material.
PCVX answered

No reply letter found.

SEC letter of Jan 17, 2020 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary, page 1
SEC asked (1)
We note your response to our prior comment 1 and continue to object to your characterization of SVX-24 as having "the potential to become the standard of care." The qualifier, "if approved," does not address our concerns that this language continues to imply that the product will be effective and will replace the current standard of care before a competing vaccine does, neither of which is appropriate at this stage
Rest of the question

of development. Please revise your registration statement to remove this language.

PCVX answered

No reply letter found.

Risk Factors Summary, page 5
SEC asked (2)
We note your response to our prior comment 5 and reissue. The risk that your intended approach will not be sufficient for regulatory approval or that regulators will require field efficacy trials or longer trials with more participants than you currently anticipate exists now. Please add a separate bullet point in this section to discuss that risk.
Rest of the question

You may contact Michael Fay at 202-551-3812 or Al Pavot at 202-551-3738 if you have questions regarding comments on the financial statements and related matters. Please contact Ada D. Sarmento at 202-551-3798 or Mary Beth Breslin at 202-551-3625 with any other questions.

PCVX answered

No reply letter found.

Prospectus Summary, page 1
SEC asked
We note your revised disclosure in response to our prior comment 1. Please remove your statements here and elsewhere in the prospectus that you believe that SVX-24, if approved, has the potential to become the most broad-spectrum pneumococcal conjugate vaccine addressing the $7 billion global pneumococcal vaccine market.
Rest of the question

Please also revise your statements here and elsewhere in the prospectus that you believe that you are developing potentially "best-in-class" vaccines. This language implies that your product candidates will be effective and will be better than competing vaccines, neither of which is appropriate at this stage of development.

PCVX answered
to the Staff’s comment, the Company has revised the existing disclosure on pages 1, 98, 103 and 111 of the Registration Statement.
Read in the reply

Also in this review: company letter, Jun 9, 2020, company letter, Jun 9, 2020

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 9 letters filed since 2019-11-08. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PCVX/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.